EXEL vs INVA: fair value comparison
Exelixis, Inc. and Innoviva, Inc. · Updated 2026-10-19
EXEL currently screens as fairly valued while INVA screens as undervalued. Within Healthcare, INVA currently sits closer to the top of our ranking by discount to fair value.
| EXEL | INVA | |
|---|---|---|
| Verdict | Fairly valued | Undervalued |
| Last price | $62.23 | $20.78 |
| 12-month range | $37.90–$62.83 | $17.57–$24.24 |
| Rank by discount to fair value | #48 of 108 Healthcare | #43 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Fairly Valued | Undervalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: EXEL fair value analysis · INVA fair value analysis